Cardiol Therapeutics Files 6-K with Exempt Distribution Report
Ticker: CRDL · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, exempt-distribution, corporate-update
TL;DR
Cardiol Therapeutics filed a 6-K on Oct 28, 2025, including an exempt distribution report (Exhibit 99.1).
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on October 28, 2025, reporting on activities for the month of October 2025. The filing includes Exhibit 99.1, a Form 45-106F1 Report of Exempt Distribution. The company's principal executive office is located in Oakville, Ontario, Canada.
Why It Matters
This filing provides an update on Cardiol Therapeutics' regulatory activities, specifically detailing an exempt distribution which could impact its share structure or financing.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain updates on financing or corporate actions, which can introduce volatility or signal changes in the company's financial health.
Key Numbers
- 001-40712 — Commission File Number (Identifies the specific SEC filing series for Cardiol Therapeutics Inc.)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- Chris Waddick (person) — Chief Financial Officer
- October 2025 (date) — Reporting period
- October 27, 2025 (date) — Filing date
- Oakville, Ontario (location) — Principal executive office
FAQ
What is the nature of the exempt distribution reported in Exhibit 99.1?
The filing does not provide details on the nature of the exempt distribution, only that a Form 45-106F1 Report of Exempt Distribution is included as Exhibit 99.1.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on October 28, 2025.
Who signed the Form 6-K on behalf of Cardiol Therapeutics Inc.?
The Form 6-K was signed by Chris Waddick, Chief Financial Officer.
What is the principal executive office address of Cardiol Therapeutics Inc.?
The principal executive office is located at 602-2265 Upper Middle Road East, Oakville, Ontario L6H 0G5, Canada.
Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
The filing indicates that the company files under Form 40-F.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2025-10-27 21:45:30
Filing Documents
- tm2518051d4_6k.htm (6-K) — 10KB
- tm2518051d4_ex99-1.htm (EX-99.1) — 32KB
- tm2518051d4_ex99-1img004.jpg (GRAPHIC) — 136KB
- tm2518051d4_ex99-1img005.jpg (GRAPHIC) — 163KB
- tm2518051d4_ex99-1img006.jpg (GRAPHIC) — 229KB
- tm2518051d4_ex99-1img007.jpg (GRAPHIC) — 115KB
- tm2518051d4_ex99-1img008.jpg (GRAPHIC) — 173KB
- tm2518051d4_ex99-1img009.jpg (GRAPHIC) — 165KB
- tm2518051d4_ex99-1img010.jpg (GRAPHIC) — 194KB
- tm2518051d4_ex99-1img011.jpg (GRAPHIC) — 135KB
- tm2518051d4_ex99-1img012.jpg (GRAPHIC) — 118KB
- 0001104659-25-102722.txt ( ) — 2009KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 27, 2025 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer Form 6-K Exhibit Index Exhibit Number Document Description 99.1 Form 45-106F1 Report of Exempt Distribution